Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

G Protein-coupled Receptor 91 (GPR91) Indicates Prognosis and Enhances Chemoresistance by Regulating DNA Damage Pathway and ERK Signaling Pathways in Neuroblastoma

ABSTRACT: G Protein-coupled Receptor 91 (GPR91) Indicates Prognosis and Enhances Chemoresistance by Regulating DNA Damage Pathway and ERK Signaling Pathways in Neuroblastoma

PROVIDER: PRJNA821488 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18537052_1.fastq.gz	Fastqsanger.gz
	SRR18537052_2.fastq.gz	Fastqsanger.gz
	SRR18537053_1.fastq.gz	Fastqsanger.gz
	SRR18537053_2.fastq.gz	Fastqsanger.gz
	SRR18537054_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

G Protein-coupled Receptor 91 (GPR91) Indicates Prognosis and Enhances Chemoresistance by Regulating DNA Damage Pathway and ERK Signaling Pathways in Neuroblastoma

Project description:This study first reveals that GPR91 is a potential oncogene in neuroblastoma, which is significantly correlated with poor prognosis and significantly represses the sensitivity to chemotherapeutic drugs including doxorubicin and cisplatin of NB cells. It is regulated by GPR91 though the DNA damage pathway and the ERK signaling pathway.

2022-04-02 | GSE199784 | GEO

TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1

Project description:The tumor necrosis factor induced protein 8 (TNFAIP8), a novel anti-apoptotic molecule, has been implicated in chemoresistance of several types of neoplasms, but its role in AML remains to be elucidated. In this study, upregulated TNFAIP8 expression was found in human AML patients and cell lines. E74 like ETS transcription factor 1 (ELF1) was identified to contribute to its aberrant expression. Forced expression of TNFAIP8 protected cells from apoptosis induced by chemotherapeutic agents and increased drug resistance. Importantly, the leukemia-promoting action of TNFAIP8 was mediated by sustaining activity of the extracellular signal-regulated kinase (ERK) signaling pathway through an interaction with Rac family small GTPase 1 (Rac1). In vivo experiments showed that TNFAIP8 suppression lowered leukemia infiltration and improved survival. Taken together, our data provide a molecular basis for the role of TNFAIP8 in chemoresistance and progression of AML and highlight the unique function of TNFAIP8 as an attractive therapeutic target.

2020-08-19 | GSE154253 | GEO

Xanthobacter sp. 91 strain:91

Project description:Xanthobacter sp. 91 strain:91 Genome sequencing and assembly

| PRJNA165239 | ENA

TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1

Project description:TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1

| PRJNA645594 | ENA

Escherichia coli strain:C-91 | isolate:C-91

Project description:Escherichia coli strain:C-91 | isolate:C-91 Genome sequencing and assembly

| PRJNA432298 | ENA

Psychrobacter celer 91

Project description:Psychrobacter celer 91 genome sequence

| PRJEB270 | ENA

Populus trichocarpa cultivar:BESC 91

Project description:Populus trichocarpa BESC 91 transcriptome - BESC 91 - young leaf

| PRJNA408780 | ENA

Vibrio crassostreae ZF-91

Project description:Vibrio crassostreae ZF-91

| PRJNA167009 | ENA

A novel regulatory axis of MSI2-AGO2/miR-30a-3p-CGRRF1 drives cancer chemoresistance by upregulating the KRAS/ERK pathway

Project description:The KRAS/ERK pathway is crucial in cancer progression and chemotherapy resistance, yet its upstream regulatory mechanism remains elusive. We identified MSI2 as a new promoter of chemotherapy resistance in cancers. MSI2 directly binds to a specific class of mature miRNAs by recognizing the 'UAG' motif and interacts with the essential effector AGO2, highlighting MSI2 as a novel regulatory factor within the miRNA pathway. Specifically, MSI2 recruits UAG-miRNA miR-30a-3p to facilitate its loading onto AGO2, efficiently inhibiting the expression of CGRRF1. Further analysis reveals that CGRRF1 functions as a new ubiquitin E3 ligase for KRAS, mediating the ubiquitination and proteasome degradation of KRAS. Consequently, a novel regulatory axis involving MSI2-AGO2/miR-30a-3p-CGRRF1 positively regulates the KRAS/ERK pathway. Remarkably, platinum-based chemotherapy drugs significantly enhance the levels of phosphorylated ERK1/2 (p-ERK1/2) in cancer cells, and the EGFR inhibitor Gefitinib also increases p-ERK1/2 levels in Gefitinib-resistant cancer cells. Combining small-molecule inhibitors targeting MSI2, such as Ro 08-2750, efficiently alleviated chemoresistance in tumor cells exposed to Platinum and Gefitinib. These findings suggest that MSI2 could be a novel therapeutic target for developing strategies to counteract cancer resistance to treatment.

2024-11-27 | GSE262884 | GEO

Nucleus-Translocated GCLM Promotes Chemoresistance in Colorectal Cancer through a Moonlighting Function

Project description:Emerging evidence indicates that metabolic enzymes perform moonlighting functions during tumor progression, including the modulation of chemoresistance. However, the underlying mechanisms of these functions remain elusive. In this study, utilizing a metabolic CRISPR-Cas9 knockout library screen, we observed that loss of Glutamate-cysteine ligase modifier subunit (GCLM), a rate-limiting enzyme in glutathione biosynthesis, noticeably heightens the sensitivity of colorectal cancer (CRC) cells to platinum-based chemotherapy. Mechanistically, we unveil a noncanonical mechanism through which nuclear GCLM competitively interacts with NF-kappa-B-repressing factor (NKRF), a known inhibitor of NF-κB signaling, to promote NF-κB activity and subsequently facilitate chemoresistance. In response to platinum drug treatment, P38 MAPK phosphorylates GCLM at T17, resulting in its recognition by importin a5 and subsequent nuclear translocation. Furthermore, elevated expression of nuclear GCLM correlates with unfavorable prognosis and poor benefit from standard chemotherapy. Overall, our work shed light on the essential nonmetabolic role and posttranslational regulatory mechanism of GCLM in enhancing NF-κB activity and subsequent chemoresistance.

2024-11-15 | PXD055376 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data